ERβ-Dependent Direct Suppression of Human and Murine Th17 Cells and Treatment of Established Central Nervous System Autoimmunity by a Neurosteroid
Authors:
- Maria AggelakopoulouMAMaria Aggelakopoulou
- Evangelia KourepiniEKEvangelia Kourepini
- Nikolaos PaschalidisNPNikolaos Paschalidis
- Davina C. M. SimoesDavina C. M. Simoes
- Dimitra KalavriziotiDKDimitra Kalavrizioti
- Nikolaos DimisianosNDNikolaos Dimisianos
- Panagiotis PapathanasopoulosPPPanagiotis Papathanasopoulos
- Athanasia MouzakiAthanasia Mouzaki
- Vily PanoutsakopoulouVPVily Panoutsakopoulou
Open Access
- 1 October 2016
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 197 (7) , 2598-2609
Abstract
Multiple sclerosis (MS), an autoimmune disease of the CNS, is mediated by autoreactive Th cells. A previous study showed that the neurosteroid dehydroepiandrosterone (DHEA), when administered preclinically, could suppress progression of relapsing-remitting experimental autoimmune encephalomyelitis (EAE). However, the effects of DHEA on human or murine pathogenic immune cells, such as Th17, were unknown. In addition, effects of this neurosteroid on symptomatic disease, as well as the receptors involved, had not been investigated. In this study, we show that DHEA suppressed peripheral responses from patients with MS and reversed established paralysis and CNS inflammation in four different EAE models, including the 2D2 TCR-transgenic mouse model. DHEA directly inhibited human and murine Th17 cells, inducing IL-10–producing regulatory T cells. Administration of DHEA in symptomatic mice induced regulatory CD4+ T cells that were suppressive in an IL-10–dependent manner. Expression of the estrogen receptor β by CD4+ T cells was necessary for DHEA-mediated EAE amelioration, as well as for direct downregulation of Th17 responses. TGF-β1 as well as aryl hydrocarbon receptor activation was necessary for the expansion of IL-10–producing T cells by DHEA. Thus, our studies demonstrate that compounds that inhibit pathogenic Th17 responses and expand functional regulatory cells could serve as therapeutic agents for autoimmune diseases, such as MS.Keywords
This publication has 51 references indexed in Scilit:
- An ADIOL-ERβ-CtBP Transrepression Pathway Negatively Regulates Microglia-Mediated InflammationCell, 2011
- Interleukin-10 Signaling in Regulatory T Cells Is Required for Suppression of Th17 Cell-Mediated InflammationImmunity, 2011
- Generation of pathogenic TH17 cells in the absence of TGF-β signallingNature, 2010
- Regulation of human Th9 differentiation by type I interferons and IL‐21Immunology & Cell Biology, 2010
- T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitisNature Medicine, 2010
- Estrogen treatment in multiple sclerosisJournal of the Neurological Sciences, 2009
- Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERα)Laboratory Investigation, 2009
- A follow-up study of chromosome 19q13 in multiple sclerosis susceptibilityJournal of Neuroimmunology, 2009
- The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivoNature Immunology, 2009
- Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammationNature Medicine, 2007